Instil Bio (TIL) Stock
Early stage biotech developing immune treatments for cancer. Here's the price, business snapshot, and what's worth knowing about Instil Bio in June 2026.
Instil Bio, Inc. (TIL) is a clinical-stage biotechnology company developing tumour-infiltrating lymphocyte (TIL) and engineered T‑cell therapies intended to treat solid tumours. The company's value proposition centres on early clinical programmes and technology that aim to harness patients' immune systems to attack cancer. With a market capitalisation around $128M, Instil is an early-stage, research-driven business: revenues are limited and valuation is sensitive to trial readouts, regulatory news and funding activity. Investors should be aware that potential upside from positive clinical data or strategic partnerships is balanced by significant risks — clinical failures, manufacturing complexity, regulatory delays and possible dilution from capital raises. This summary is for general educational purposes only and not personal investment advice. It’s important to consider your own risk tolerance, diversify holdings and seek independent financial advice before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Instil Bio's stock, expecting it to rise significantly in value.
Financial Health
Instil Bio is showing strong financial performance with solid cash flow and book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring TIL
Biotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.
Published: 17 November 2025
Explore BasketPharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: 5 October 2025
Explore BasketPharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: 29 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical readouts matter
Early-stage trial results largely determine valuation; strong data can create upside, but outcomes are binary and unpredictable.
Manufacturing and scale challenges
Cell therapies require specialised manufacturing and scale-up, which can delay timelines and raise costs; these operational issues are material risks.
Partnerships can de‑risk
Collaborations or licensing deals may provide funding and validation, though they are not guaranteed and depend on clinical and commercial progress.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
